NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS

Not Yet RecruitingN/A

Sponsor: Ondokuz Mayıs University

Conditions: Multiple Sclerosis

This study aimed to investigate whether the biomarkers GFAP, NfL, and VEGF-recently considered important guides for better understanding the pathophysiology of MS-also serve as indicators of clinical progression in MS.

Eligibility overview

Sex: ALL

Age: 18 Years to 60 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Confirmed diagnosis of MS
* Progressive type MS
* Voluntary participation
* Age between 18-60 years
* Cooperative
* EDSS score ≥ 5.5

Exclusion Criteria:

* Presence of another neurological disorder
* Change in medication within the last 3 months
* Relapse within the last 3 months